A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

Sponsor
Novo Nordisk A/S
Study ID
NCT03888157
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.

Study Details

The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor. The study will last for about 5 to 8 months. Patients will be asked to complete some questionnaires about their health and diabetes treatment. Patients will complete these during their normally scheduled visits with study doctor.

Key Dates

Start date
Mar 10, 2019
Status verified
Jul 2021
Primary completion
Oct 21, 2020
Completion
Oct 21, 2020

Study Design

Enrollment
839 participants (actual)

Arms

  • Arm: Liraglutide
    Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.

Primary Outcome Measure

Change in glycated haemoglobin A1c (HbA1c) (percentage) [ Time Frame: Week 0, week 26 ]

Related Studies